INTRODUCTION {#S1}
============

Preterm birth is a leading cause of perinatal morbidity and mortality worldwide ([@R11]; [@R80]). Preterm neonates are at high risk for multiple short- and long-term complications, accounting for more than two million neonatal deaths in 2010 and representing an enormous burden for society and the health care system ([@R63]). Preterm birth is preceded by spontaneous preterm labor (PTL), a syndrome of multiple putative etiologies ([@R111]). Among these, only acute pathological inflammation (i.e., intra-amniotic infection/inflammation and clinical chorioamnionitis) has been well characterized and causally linked to preterm labor ([@R108]; [@R56]; [@R20]; [@R90]; [@R27]). The remaining etiologies are poorly understood; therefore, most cases of preterm birth (approximately 60%) are characterized as idiopathic ([@R45]; [@R7]). A breakdown of maternal-fetal tolerance has been suggested as a mechanism of disease for idiopathic preterm labor and birth ([@R111]; [@R48]). However, to date, no causal evidence has been provided connecting impaired maternal-fetal tolerance with preterm labor/birth and its adverse perinatal outcomes.

Maternal-fetal tolerance is established locally (e.g., the maternal-fetal interface) and systemically by the mother toward the allogeneic conceptus ([@R16]; [@R13]; [@R1]; [@R153]; [@R106]; [@R67]; [@R124], [@R125]; [@R121]; [@R117]). At the maternal-fetal interface, this tolerance is sustained by an immune repertoire composed of regulatory T cells (Tregs) ([@R1]; [@R122]; [@R60]; [@R140]; [@R120]), as well as homeostatic innate immune cells such as macrophages ([@R65]; [@R57]; [@R62]; [@R136]; [@R137]; [@R148]), natural killer (NK) cells ([@R69]; [@R79]), and innate lymphoid cells ([@R142]; [@R28]; [@R149]; [@R84]). To date, most research has focused on investigating the processes of maternal-fetal tolerance during early pregnancy ([@R153]; [@R67]; [@R124]; [@R121]; [@R117]; [@R18]), given that this is the period in which the growing conceptus educates the maternal immune system to sustain pregnancy and promote its survival ([@R3]; [@R107]; [@R141]). However, the role of Tregs later in gestation (third trimester in humans and third week in mice) has not been mechanistically investigated.

Clinical studies have shown a negative association between the numbers and/or function of peripheral Tregs and the diagnosis of PTL leading to preterm birth ([@R146]; [@R123]; [@R135]; [@R46]). However, whether Tregs are reduced in number and/or function at the maternal-fetal interface (i.e., decidua) in women with PTL is unknown. Herein, we undertook an extensive investigation that included both human decidual samples from different subsets of PTL and animal models, which allowed us to provide translational and mechanistic evidence of a role for Tregs in the pathophysiology of idiopathic preterm labor/birth and adverse neonatal outcomes.

RESULTS {#S2}
=======

Functional Tregs Are Reduced at the Maternal-Fetal Interface in a Subset of Women with Idiopathic PTL and birth {#S3}
---------------------------------------------------------------------------------------------------------------

The maternal-fetal interface represents the site of immune interactions between the mother and the conceptus ([@R17]; [@R97]; [@R32]; [@R101]; [@R12]). The human maternal-fetal interface includes (1) the decidua parietalis, the area of contact between the endometrium and the chorioamniotic membranes, and (2) the decidua basalis, the interface between the endometrium and the placenta ([@R127]; [@R47]). Different subsets of Tregs have been localized in both the decidua basalis ([@R128]; [@R122]; [@R138], [@R139]; [@R66]; [@R140]; [@R120]) and the decidua parietalis ([@R128]; [@R60]; [@R138], [@R139]; [@R120]); however, their suppressive activity has yet to be established. We first tested whether third-trimester-derived decidual Tregs had suppressive activity. Decidual Tregs were sorted from preterm and term decidual tissues ([Table S1](#SD1){ref-type="supplementary-material"}) and co-cultured with matched isolated effector T cells (Teffs) ([Figure 1A](#F1){ref-type="fig"}), and the percentage of suppression was calculated (see [STAR Methods](#S16){ref-type="sec"}). Decidual Tregs exhibited suppressive activity at a 1:1 Treg:Teff ratio, yet such a function seemed to be lower in preterm pregnancies compared to term pregnancies ([Figure 1B](#F1){ref-type="fig"}). These data show that third-trimester decidual Tregs display suppressive activity toward Teffs at the human maternal-fetal interface.

Next, we investigated whether Tregs were altered at the maternal-fetal interface of women who underwent the pathological (preterm) or physiological (term) process of labor. To address this research question, we collected decidual tissues from women with PTL and birth or term labor/birth (TIL), as well as gestational age-matched non-labor controls (preterm without labor \[PTNL\] or term without labor \[TNL\]) ([Table S2](#SD1){ref-type="supplementary-material"}). Given that the process of labor can occur in the setting of acute inflammation of the placenta ([@R73]), resulting from intra-amniotic inflammation/infection, the well-known etiology of preterm birth ([@R109]), we subdivided the preterm and term labor groups according to the presence or absence of acute chorioamnionitis (AI) ([Table S2](#SD1){ref-type="supplementary-material"}). Idiopathic PTL (iPTL) was subdivided by the presence (iPTL+CI) or absence (iPTL) of chronic chorioamnionitis (CI) ([@R74]), a placental lesion associated with maternal anti-fetal rejection ([@R77]). Neither of the iPTL groups included the presence of acute inflammation of the placental tissues. Leukocytes were isolated from the decidua basalis and decidua parietalis based on our previously established method ([@R147]), and flow cytometry was used to determine the frequencies of Tregs (CD45+CD3+CD4+CD25+Foxp3+ cells) ([Figure 1C](#F1){ref-type="fig"}). In the decidua parietalis, Tregs were significantly reduced in women with iPTL+CI compared to non-labor controls ([Figure 1D](#F1){ref-type="fig"}). A slight non-significant reduction in Tregs was also observed in women with iPTL compared to non-labor controls ([Figure 1D](#F1){ref-type="fig"}). Moreover, in the decidua basalis, Tregs tended to be reduced in women with iPTL ([Figure 1E](#F1){ref-type="fig"}). Decidual Tregs were also reduced in women whose placentas displayed acute inflammatory lesions ([Figure 1D](#F1){ref-type="fig"}), as previously shown in the uterine tissues of mice injected with an endotoxin (animal model of acute systemic inflammation-induced preterm birth) ([@R5]). No differences were observed among the term groups ([Figures 1F](#F1){ref-type="fig"} and [1G](#F1){ref-type="fig"}). These findings show that Tregs are reduced at the maternal-fetal interface in a subset of women who underwent the pathological process of idiopathic PTL and birth, but not in those who underwent the physiological process of labor at term.

Tc17 Cells Are Increased at the Maternal-Fetal Interface in Women with Idiopathic PTL and birth {#S4}
-----------------------------------------------------------------------------------------------

It has been proposed that a balance exists during normal pregnancy between homeostatic Tregs and pro-inflammatory Th17 cells, and a breakdown of this balance leads to obstetrical disease ([@R118]; [@R37]). Therefore, we investigated whether the reduction in decidual Tregs in women with PTL and birth was accompanied by a concomitant increase in decidual Th17 cells. Flow cytometry was performed to determine the frequencies of Th17 cells (CD45+CD3+CD4+IL-17A+ cells) ([Figure 2A](#F2){ref-type="fig"}) in the decidua ([Table S2](#SD1){ref-type="supplementary-material"}). Neither the decidua parietalis nor the decidua basalis displayed significant changes in the frequencies of Th17 cells among the preterm and term study groups ([Figures 2B](#F2){ref-type="fig"}--[2E](#F2){ref-type="fig"}). Given that interleukin (IL)-17A is also produced by CD8+ T cells, Tc17 cells (CD45+CD3+CD8+IL-17A+ cells), and that such cells display a pro-inflammatory phenotype ([@R58]; [@R64]), these cells were identified in the decidua ([Figure 2A](#F2){ref-type="fig"}). Consistently, both in the decidua parietalis and decidua basalis, the frequencies of Tc17 cells were greater in women with iPTL compared to non-labor controls ([Figures 2F](#F2){ref-type="fig"} and [2G](#F2){ref-type="fig"}). Again, no differences were observed in the frequencies of Tc17 cells among the term study groups ([Figures 2H](#F2){ref-type="fig"} and [2I](#F2){ref-type="fig"}). These findings show that an imbalance between functional Tregs and Tc17 cells occurs at the maternal-fetal interface in women with idiopathic PTL and birth.

Establishment of a Model to Study the Role of Systemic Tregs in Late Pregnancy {#S5}
------------------------------------------------------------------------------

Together with clinical studies ([@R146]; [@R123]; [@R135]; [@R46]), our first set of data ([Figure 1](#F1){ref-type="fig"}) indicates that women with PTL and birth have reduced Tregs both in the peripheral circulation and at the maternal-fetal interface. Next, we undertook *in vivo* experimentation to demonstrate a causal link between systemic Tregs and preterm birth.

Previous studies showed that the systemic depletion of Tregs before implantation or in early gestation results in failure to implant or pregnancy loss ([@R153]; [@R25]; [@R67]; [@R124]; [@R116], [@R117]; [@R121]; [@R18]). However, to date, no studies have established a role for systemic Tregs in the third week of murine pregnancy (i.e., third trimester in humans). An earlier study depleted allogeneic CD25+ T cells on 10.5 and 13.5 days postcoitum (dpc), and no adverse pregnancy outcomes were recorded ([@R124]). A possible explanation as to why the depletion of CD25+ T cells did not cause disease in the previously mentioned study is that the depletion of CD25+ T cells is incomplete and not specific for Foxp3+ Tregs ([@R75]; [@R21]; [@R34]). Alternatively, it could be that Tregs were not functional during the third week of murine pregnancy, as they were in earlier pregnancy ([@R99]). Therefore, we first determined whether murine Tregs displayed suppressive activity in the second and third weeks of pregnancy ([Figure S1A](#SD1){ref-type="supplementary-material"}). As expected, second-week-derived Tregs suppressed Teff proliferation ([Figure S1B](#SD1){ref-type="supplementary-material"}). Third-week-derived Tregs also suppressed Teff proliferation ([Figure S1C](#SD1){ref-type="supplementary-material"}). Indeed, at a 1:8 Treg:Teff ratio, third-week-derived Tregs were more suppressive than second-week-derived Tregs ([Figure S1D](#SD1){ref-type="supplementary-material"}). Thus, Tregs are functional during the second and third weeks of murine pregnancy.

We then proceeded to establish a murine model in which the partial or total depletion of Tregs can be achieved in the third week of pregnancy. We reasoned that the partial depletion of Tregs will resemble the clinical condition in which women have reduced Tregs (e.g., PTL) ([Figure 1](#F1){ref-type="fig"}), whereas the total depletion of Tregs will allow us to definitively establish a role for such cells in pregnancy. We used *Foxp3*^*DTR*^ mice ([@R70]), in which the administration of diphtheria toxin (DT) allows for depletion of all Foxp3+ Tregs. The administration of 25 μg/kg ([@R116], [@R117]) or 50 μg/kg ([@R70]; [@R121]) of DT to naive non-pregnant *Foxp3*^*DTR*^ mice induced the partial or total depletion of Tregs, respectively, as indicated by the reduction of these cells in the uterine-draining lymph nodes (ULNs), spleen, and thymus ([Figure S2](#SD1){ref-type="supplementary-material"}). Next, we mated *Foxp3*^*DTR*^ females with BALB/c males to obtain an allogeneic pregnancy ([Figure 3A](#F3){ref-type="fig"}; [Figure S3A](#SD1){ref-type="supplementary-material"}). To induce the partial or total depletion of Tregs, *Foxp3*^*DTR*^ dams were injected with 25 or 50 μg/kg of DT on 14.5 dpc, followed by daily administration of 5 or 50 μg/kg of DT, respectively, until delivery ([Figure 3A](#F3){ref-type="fig"}; [Figure S3A](#SD1){ref-type="supplementary-material"}). The partial or total depletion of Tregs was confirmed in the decidua, myometrium, peripheral blood, and placenta ([Figure 3B](#F3){ref-type="fig"}), as well as the ULNs, inguinal lymph nodes, mesenteric lymph nodes, spleen, and thymus ([Figures S3B](#SD1){ref-type="supplementary-material"}--[S3F](#SD1){ref-type="supplementary-material"}). These experiments established the murine models to study the role of Tregs in the third week of pregnancy (i.e., third trimester in humans, when the onset of preterm labor occurs).

Systemic Depletion of Tregs Induces a Fraction of Preterm Births and Causes Adverse Neonatal Outcomes in the First Pregnancy {#S6}
----------------------------------------------------------------------------------------------------------------------------

During the first pregnancy, the partial or total depletion of Tregs in the third week induced a 15% or 10% rate of preterm birth, respectively ([Figure 3C](#F3){ref-type="fig"}). In addition, neonates born to partially or totally Treg-depleted *Foxp3*^*DTR*^ dams displayed increased mortality from birth to three weeks of age ([Figure 3D](#F3){ref-type="fig"}). However, no differences were observed between those born to partially and those born to totally Treg-depleted *Foxp3*^*DTR*^ dams ([Figure 3D](#F3){ref-type="fig"}). Moreover, surviving neonates born to partially or totally Treg-depleted *Foxp3*^*DTR*^ dams were leaner than those from controls at one, two, and three weeks postpartum ([Figures 3E](#F3){ref-type="fig"}--[3G](#F3){ref-type="fig"}), but this effect was more drastic in neonates born to totally Treg-depleted *Foxp3*^*DTR*^ dams ([Figures 3F](#F3){ref-type="fig"}--[3G](#F3){ref-type="fig"}). Given the adverse effects of the depletion of Tregs on neonatal outcomes, we also investigated whether the partial or total depletion of Tregs affected fetal growth *in utero*. Representative images of the fetuses and placentas from control (PBS), partially Treg-depleted, or totally Treg-depleted *Foxp3*^*DTR*^ dams are shown in [Figure 3H](#F3){ref-type="fig"}. Fetuses from partially and totally Treg-depleted *Foxp3*^*DTR*^ dams were smaller and leaner than those from controls ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}), indicating that the depletion of Tregs affects fetal growth. However, placental weights were similar between controls and Treg-depleted mice ([Figure 3J](#F3){ref-type="fig"}). These results show that the partial or total depletion of Tregs in the third week of the first pregnancy induces a fraction of preterm birth and, importantly, adverse fetal and neonatal outcomes.

Systemic Depletion of Tregs Induces a Fraction of Preterm Births and Causes Adverse Neonatal Outcomes in Repeat Pregnancies {#S7}
---------------------------------------------------------------------------------------------------------------------------

A prior study has shown that Tregs undergo an accelerated expansion during the second pregnancy, which confers resilience against pregnancy loss ([@R117]). Therefore, we reasoned that the total depletion of Tregs during the first and second pregnancy will worsen the rate of preterm birth and/or adverse neonatal outcomes observed during the first pregnancy. To examine this research question, Tregs were partially or totally depleted during the first and second pregnancy. The repeated partial or total depletion of Tregs induced comparable rates of preterm birth to the first pregnancy (15% and 14%, respectively) ([Figure 3C](#F3){ref-type="fig"}). As observed in the first pregnancy, neonates born to partially and totally Treg-depleted *Foxp3*^*DTR*^ dams during repeat pregnancies had higher rates of mortality compared to controls ([Figure 3D](#F3){ref-type="fig"}). The repeated total depletion of Tregs in the first and second pregnancy induced a greater rate of neonatal mortality than the partial depletion of Tregs, a phenomenon that was not observed during the first pregnancy ([Figure 3D](#F3){ref-type="fig"}). Like the first pregnancy, surviving neonates from partially or totally Treg-depleted *Foxp3*^*DTR*^ dams during repeat pregnancies were leaner than their control counterparts at weeks one, two, and three postpartum ([Figures 3E](#F3){ref-type="fig"}--[3G](#F3){ref-type="fig"}). These results show that the repeated partial or total depletion of Tregs in the first and second pregnancy results in rates of preterm birth that are comparable to those of the first pregnancy. Nonetheless, the total depletion of Tregs in the first and second pregnancy had more deleterious effects on neonatal survival than the depletion of such cells in the first pregnancy alone.

The Adoptive Transfer of Tregs Prevents Preterm Birth and Adverse Neonatal Outcomes {#S8}
-----------------------------------------------------------------------------------

Next, we evaluated whether the adoptive transfer of Tregs could prevent the adverse pregnancy outcomes induced by the depletion of such cells. Tregs were isolated from allogeneic pregnancies and adoptively transferred to partially Treg-depleted *Foxp3*^*DTR*^ dams on 14.5 and 16.5 dpc, and pregnancy outcomes were recorded ([Figure 4A](#F4){ref-type="fig"}). The rate of preterm birth in partially Treg-depleted *Foxp3*^*DTR*^ dams was rescued by the adoptive transfer of Tregs (15% versus 0%) ([Figure 4B](#F4){ref-type="fig"}). Moreover, neonatal survival at one, two, and three weeks of age was significantly improved after the adoptive transfer of Tregs ([Figure 4C](#F4){ref-type="fig"}). The proportion of adoptively transferred Tregs was also determined using EGFP-expressing mice (see [STAR Methods](#S16){ref-type="sec"} and [Key Resources Table](#T1){ref-type="table"}) ([Figure 4D](#F4){ref-type="fig"}). Adoptively transferred Tregs were observed in the peripheral blood, ULNs, spleen, decidua, myometrium, and placenta ([Figure 4E](#F4){ref-type="fig"}). These results provide a mechanistic demonstration that Tregs play a role in the timing of parturition and neonatal survival.

Systemic Depletion of Tregs Increases the Susceptibility to Endotoxin-Induced Preterm Birth {#S9}
-------------------------------------------------------------------------------------------

The depletion of Tregs did not always induce preterm birth ([Figure 3C](#F3){ref-type="fig"}). Therefore, we reasoned that the loss of such cells, in some cases, could increase the susceptibility to lipopolysaccharide (LPS or endotoxin)-induced preterm birth. Partially Treg-depleted *Foxp3*^*DTR*^ dams received a mild dose of LPS (that does not cause preterm birth in wild-type mice) on 16.5 dpc and were monitored until delivery ([Figure S4A](#SD1){ref-type="supplementary-material"}). The injection of LPS in Treg-depleted *Foxp3*^*DTR*^ dams induced a 33% rate of preterm birth, whereas all non-Treg-depleted *Foxp3*^*DTR*^ dams delivered at term ([Figure S4B](#SD1){ref-type="supplementary-material"}). Moreover, the injection of LPS caused a higher rate of neonatal mortality in Treg-depleted *Foxp3*^*DTR*^ dams than in non-Treg-depleted *Foxp3*^*DTR*^ dams ([Figure S4C](#SD1){ref-type="supplementary-material"}). *Foxp3*^*DTR*^ dams injected with DT alone (on 14.5 and 15.5 dpc) did not deliver preterm, and their neonates thrived for up to 3 weeks, as controls did (data not shown). These findings indicate that the depletion of Tregs also increases the susceptibility of the mother to deliver preterm upon encountering inflammatory agents (e.g., bacterial infection).

Systemic Depletion of Tregs Does Not Negatively Affect Maternal Obstetrical Parameters {#S10}
--------------------------------------------------------------------------------------

Previous studies have shown that the long-term depletion of Tregs induces systemic disease ([@R70]; [@R55]), including severe acute inflammation ([@R70]). This finding raised the question as to whether the total or partial depletion of Tregs used in the current study could cause systemic acute disease that, in turn, may be the cause of mice delivering preterm. We argue that this could not be the case because the Treg depletion used herein was solely performed during the third week of pregnancy. Nonetheless, we conducted a series of obstetrical determinations that are commonly performed in pregnant women to evaluate maternal and fetal well-being ([@R132]; [@R100]). Partially and totally Treg-depleted *Foxp3*^*DTR*^ dams, as well as control dams, underwent body temperature monitoring, blood pressure determination, and high-resolution ultrasound imaging ([Figure 5A](#F5){ref-type="fig"}) (see [STAR Methods](#S16){ref-type="sec"}). Systemic acute inflammation induces hypothermia in mice ([@R53]); however, the depletion of Tregs did not cause hypothermia. Thus, partially and totally Treg-depleted *Foxp3*^*DTR*^ dams displayed body temperature similar to that of control dams ([Figure 5B](#F5){ref-type="fig"}). In addition, partially and totally Treg-depleted *Foxp3*^*DTR*^ dams had blood pressure similar to that of control dams ([Figure 5C](#F5){ref-type="fig"}). Uterine artery Doppler allowed the determination of the maternal heart rate and uterine artery pulsatility index ([Figure 5D](#F5){ref-type="fig"}). Partially and totally Treg-depleted *Foxp3*^*DTR*^ dams had heart rates similar to those of control dams ([Figure 5E](#F5){ref-type="fig"}). Totally Treg-depleted *Foxp3*^*DTR*^ dams had reduced uterine artery pulsatility indices compared to control dams ([Figure 5F](#F5){ref-type="fig"}). However, only an increased uterine artery Doppler is associated with hypertensive disorders (e.g., preeclampsia) and adverse perinatal outcomes ([@R100]). Umbilical artery Doppler allowed the determination of the fetal heart rate and umbilical artery pulsatility index ([Figure 5G](#F5){ref-type="fig"}). Fetuses of totally, but not partially, Treg-depleted *Foxp3*^*DTR*^ dams were bradycardic (reduced heart rates compared to controls) ([Figure 5H](#F5){ref-type="fig"}), which is consistent with our earlier observations showing that Treg depletion causes fetal compromise ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}). However, fetuses of partially and totally Treg-depleted *Foxp3*^*DTR*^ dams displayed umbilical artery pulsatility indices similar to those of control fetuses ([Figure 5I](#F5){ref-type="fig"}). The latter finding is relevant, because an abnormal umbilical artery pulsatility index is associated with a cytokine storm in the maternal circulation ([@R49]), indicating that Treg depletion is not associated with severe acute inflammation in the maternal circulation.

The long-term depletion of Tregs causes splenomegaly ([@R70]); therefore, we also evaluated the size of the spleens and ULNs. Partially and totally Treg-depleted *Foxp3*^*DTR*^ dams had a similar-sized spleen compared to control dams, but ULNs of totally Treg-depleted dams were slightly enlarged ([Figure 5J](#F5){ref-type="fig"}). However, neonates of partially or totally Treg-depleted *Foxp3*^*DTR*^ dams that survived were breastfed by the dams ([Figure 5K](#F5){ref-type="fig"}; see milk band indicating that newborns were breastfed).

These physiological determinations show that the depletion of Tregs during the third week of pregnancy neither negatively affects maternal obstetrical parameters nor induces splenomegaly or alters breastfeeding, yet it induces fetal compromise.

Systemic Depletion of Tregs Induces a Mild Inflammatory Response in the Maternal Circulation that Can Induce Early-Term Delivery {#S11}
--------------------------------------------------------------------------------------------------------------------------------

Next, we investigated whether the depletion of Tregs alters cytokine responses in the maternal circulation. This question arose from some cases of preterm labor being characterized by diverse inflammatory responses in the maternal circulation ([@R42]; [@R131]; [@R23]; [@R19]; [@R94]). However, these systemic immune responses vary between subsets of preterm labor; therefore, the determination of specific cytokines in the maternal circulation is not useful to predict preterm birth. Regardless, we reasoned that by using targeted approaches (e.g., Treg depletion), we may be able to observe stereotypical immune responses in the maternal circulation that may other-wise be difficult to identify in humans. *Foxp3*^*DTR*^ dams underwent partial or total depletion of Tregs, and in preterm gestations, the maternal plasma was collected for determination of 36 cytokines using a multiplex system (see [STAR Methods](#S16){ref-type="sec"} and [Key Resources Table](#T1){ref-type="table"}). Consistent with our hypothesis, the depletion of Tregs did not increase the conventional acute pro-inflammatory cytokines IL-6, CCL2, IL-1β, and tumor necrosis factor alpha (TNF-α) in the maternal circulation ([Figures 6A](#F6){ref-type="fig"}--[6D](#F6){ref-type="fig"}). As expected ([@R40]), these and other acute pro-inflammatory cytokines were increased in a model of endotoxin-induced preterm birth, but not in the partially or totally Treg-depleted *Foxp3*^*DTR*^ dams ([Figure S5](#SD1){ref-type="supplementary-material"}). Interestingly, totally Treg-depleted *Foxp3*^*DTR*^ dams displayed higher plasma concentrations of interferon gamma (IFNγ), CCL7, and IL-22 compared to control dams ([Figures 6E](#F6){ref-type="fig"}--[6G](#F6){ref-type="fig"}). The plasma concentrations of IL-10 (a cytokine produced by Tregs) ([@R68]) tended to be reduced in Treg-depleted *Foxp3*^*DTR*^ dams; however, this reduction did not reach statistical significance ([Figure 6H](#F6){ref-type="fig"}). To complement these observations, we tested whether systemic administration of IFNγ, CCL7, and IL-22 at pathological concentrations (concentrations found in the maternal circulation upon Treg depletion) could induce preterm birth and neonatal mortality (see [STAR Methods](#S16){ref-type="sec"} and [Key Resources Table](#T1){ref-type="table"}), as Treg depletion does. Systemic administration of CCL7 and IL-22, but not IFNγ, shortened the gestational length but was insufficient to induce preterm birth (i.e., delivery before 18.5 dpc) ([Figure 6I](#F6){ref-type="fig"}). Thus, a fraction of dams injected with CCL7 and/or IL-22 underwent early-term delivery ([Figure 6J](#F6){ref-type="fig"}). However, pups born to dams injected with CCL7 and/or IL-22 did not show significantly higher mortality rates at birth compared to controls ([Figure 6K](#F6){ref-type="fig"}). The combined administration of CCL7 and IL-22 resulted in similar outcomes to those observed with the single administration of each cytokine (data not shown). Collectively, these results indicate that the mild inflammatory response observed in Treg-depleted dams partially participates in the timing of parturition but alone is not sufficient to induce preterm birth or neonatal mortality.

Systemic Depletion of Tregs Does Not Cause Intra-amniotic Inflammation {#S12}
----------------------------------------------------------------------

Until this point, we have shown that the depletion of Tregs causes fetal compromise and adverse neonatal outcomes in the absence of a severe acute inflammatory response in the maternal circulation. This scenario resembles the subclinical presentation of PTL ([@R7]). However, some of these cases occur in the presence of localized sterile intra-amniotic inflammation ([@R114]). Therefore, we next explored whether the partial or total depletion of Tregs affects the cytokine network in the amniotic cavity. *Foxp3*^*DTR*^ dams underwent partial or total depletion of Tregs, and in preterm gestations, amniotic fluid was collected to determine 36 cytokines by using a multiplex system (see [STAR Methods](#S16){ref-type="sec"} and [Key Resources Table](#T1){ref-type="table"}). The depletion of Tregs did not induce an intra-amniotic inflammatory response ([Figures 6L](#F6){ref-type="fig"}--[6S](#F6){ref-type="fig"}). Indeed, pro-inflammatory cytokines---IL-6 ([@R152]; [@R43]; [@R20]; [@R112], [@R113]), CXCL10 ([@R72]; [@R115]), CCL2 ([@R33]), and others ([@R110], [@R114]; [@R22]; [@R30])---that have been reported to be elevated in some cases of intra-amniotic inflammation/infection-associated preterm labor were unchanged in Treg-depleted dams compared to controls ([Figures 6L](#F6){ref-type="fig"}--[6Q](#F6){ref-type="fig"}). Stereotypical anti-inflammatory cytokines, namely, IL-10 ([@R24]; [@R26]; [@R144]) and IL-4 ([@R59]; [@R35]), were also unchanged upon the depletion of such cells ([Figures 6R](#F6){ref-type="fig"} and [6S](#F6){ref-type="fig"}). These results show that the reduction of Tregs can lead to adverse perinatal outcomes in the absence of an intra-amniotic inflammatory response, resembling idiopathic PTL.

Systemic Depletion of Tregs Induces Specific Cellular Immune Responses at the Maternal-Fetal Interface, in the Placenta, and in the Maternal Circulation {#S13}
--------------------------------------------------------------------------------------------------------------------------------------------------------

To further explore the mechanisms whereby the loss of Tregs induces adverse perinatal outcomes, we explored the cellular repertoire at the maternal-fetal interface, in the placenta, and in the maternal circulation. This research question was based on previous studies showing that PTL involves stereotypical cellular responses at the maternal-fetal interface ([@R5], [@R6]; [@R133]; [@R148]; [@R51]; [@R105]; [@R40]; [@R149]; [@R78]; [@R129]), in the placenta ([@R119]; [@R103]; [@R71], [@R74]; [@R44]), and in the maternal circulation ([@R42]; [@R98]). *Foxp3*^*DTR*^ dams underwent partial or total depletion of Tregs, and the decidua, myometrium, placenta, and peripheral blood were collected in preterm gestations. Immunophenotyping was performed, and data were represented in heatmaps (see [STAR Methods](#S16){ref-type="sec"}). Overall, the partial or total depletion of Tregs in *Foxp3*^*DTR*^ dams induced specific immune alterations in the cellular repertoire among compartments ([Figure 7A](#F7){ref-type="fig"}; [Figure S6](#SD1){ref-type="supplementary-material"}). Specifically, the partial depletion of Tregs in *Foxp3*^*DTR*^ dams reduced Arg1+ B cells and increased total macrophages in the decidual tissues ([Figure 7A](#F7){ref-type="fig"}). In the myometrium, the total depletion of Tregs consistently reduced transforming growth factor β (TGF-β)+ and IL-10+ CD4+ T cells ([Figure S6](#SD1){ref-type="supplementary-material"}), as well as Arg1+ neutrophils ([Figure 7A](#F7){ref-type="fig"}). In the maternal circulation, the depletion of Tregs caused the reduction of inducible nitric oxide synthase (iNOS)+ dendritic cells and an increase in TNF-α+ B cells ([Figure 7A](#F7){ref-type="fig"}). Similar to the maternal circulation, Treg depletion induced cellular responses in the placental tissues; however, these changes did not hold statistical significance after adjustment for multiple comparisons ([Figure 7A](#F7){ref-type="fig"}). Altogether, these data show that Tregs modulate the expression of specific mediators by immune cells present at the maternal-fetal interface, in the placenta, and in the maternal circulation.

RNA-Seq Analysis Reveals that Tregs Are Central for Regulation of Developmental and Cellular Processes in the Placenta {#S14}
----------------------------------------------------------------------------------------------------------------------

The loss of Tregs induces fetal growth restriction ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}), whose pathophysiology involves placental disease ([@R14]). Therefore, we next used RNA sequencing (RNA-seq) to survey the molecular processes dysregulated in the placenta upon Treg depletion (see [STAR Methods](#S16){ref-type="sec"}). The partial depletion of Tregs caused mild dysregulation of the placental transcriptome ([Figures 7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}; [Tables S3](#SD2){ref-type="supplementary-material"} and [S4](#SD3){ref-type="supplementary-material"}). However, the total depletion of Tregs caused significant dysregulation of several physiological processes in the placenta ([Figures 7B](#F7){ref-type="fig"} and [7D](#F7){ref-type="fig"}). Specifically, total depletion of Tregs induced the upregulation of 568 genes and the downregulation of 286 genes ([Figure 7D](#F7){ref-type="fig"}; [Tables S5](#SD4){ref-type="supplementary-material"} and [S6](#SD5){ref-type="supplementary-material"}). The dysregulated pathways included embryo development ending in birth, anatomical structure formation involved in morphogenesis, cellular macromolecule localization, cellular metabolic process, cellular component biogenesis, and actin cytoskeleton organization ([Figure 7E](#F7){ref-type="fig"}; [Tables S7](#SD6){ref-type="supplementary-material"} and [S8](#SD7){ref-type="supplementary-material"}). This last set of data demonstrates that Tregs play a role in fetal life and provides a possible explanation as to why the offspring of Treg-depleted dams display impaired growth and, more importantly, adverse neonatal outcomes.

DISCUSSION {#S15}
==========

This study provides descriptive and mechanistic evidence showing a role for Tregs in the pathophysiology of a subset of idiopathic preterm labors/births and adverse neonatal outcomes. First, we showed that functional Tregs are reduced at the human maternal-fetal interface in a subset of women with idiopathic PTL and birth. This finding is consistent with previous clinical reports showing that women with PTL display a reduction in the suppressive activity of peripheral Tregs ([@R123]; [@R46]). Therefore, both peripheral and local Tregs are reduced in women who undergo spontaneous PTL and birth. However, the reduction in Tregs at the maternal-fetal interface does not occur in the physiological process of labor at term. This latter finding is in line with the hypothesis that some cases of preterm labor are mediated through a mechanism different from term parturition ([@R61]; [@R52]; [@R151]; [@R145]; [@R93]; [@R96]). The most marked reduction of Tregs occurred at the area of contact between the endometrium and the fetal chorioamniotic membranes (i.e., decidua parietalis) in the presence of chronic inflammation of the placenta, which is a pathological process mediated by effector activated T cells ([@R74]; [@R6]). These data allowed us to hypothesize that the decline in Tregs in the decidua parietalis is accompanied by augmented T-cell responses at the maternal-fetal interface in a subset of women who underwent idiopathic PTL and birth.

Effector memory CD4+ and CD8+ T cells are present at the human maternal-fetal interface in term and preterm gestations ([@R143]; [@R6]; [@R129]). These T cells are increased in women with preterm labor, leading to preterm birth ([@R6]). In the current study, we provide further data indicating that decidual CD8+ T cells expressing IL-17A are implicated in the pathophysiology of preterm parturition in the absence of acute inflammation in the placenta (i.e., idiopathic preterm birth). In addition to the inflammatory cytokine IL-17A ([@R150]; [@R38]; [@R91]; [@R82]), most Tc17 cells secrete pro-inflammatory mediators such as TNF-α and IL-2 but have reduced cytotoxic activity ([@R58]; [@R64]); therefore, we suggest that the imbalance between Tregs and Tc17 cells at the human maternal-fetal interface creates a hostile inflammatory milieu that leads to preterm parturition, even in the absence of acute inflammation in the placenta or amniotic cavity. This study demonstrates that Tc17 cells participate in the pathophysiology of preterm birth, yet further research is required to reveal their specific functions during pregnancy.

Consistent with the human findings, the depletion of Tregs during the third week of pregnancy induced preterm birth that was restored upon the adoptive transfer of such cells. The rates of preterm birth resulting from the depletion of Tregs were modest compared to animal models of systemic and local acute inflammation-induced preterm birth ([@R133]; [@R49], [@R50], [@R53], [@R54]; [@R40]). However, this is consistent with the current belief that different subsets of preterm labor and birth are mediated through different mechanisms ([@R111]). Thus, in line with this concept, the depletion of Tregs should be responsible only for a subset of idiopathic preterm labors and births. The partial and total depletion of Tregs induced similar rates of preterm birth, which suggests that only a fraction of Tregs need to be depleted to cause preterm birth, regardless of parity. This is relevant to the clinical scenario, in which both nulliparous and multiparous women can present with PTL associated with a reduction of Tregs.

Importantly, the depletion of Tregs induces a fraction of preterm births in the absence of severe systemic acute inflammation, alterations in obstetrical parameters, and intra-amniotic inflammation. These features resemble the clinical scenario of idiopathic PTL ([@R7]), which is not observed in other established animal models of preterm birth, such as systemic inflammation-induced ([@R6]), acute intra-amniotic inflammation-induced ([@R40]; [@R53]), and progesterone antagonist-induced ([@R6]) preterm birth, as well as in another acute inflammatory model ([@R133]). Therefore, we surmise that the loss of Tregs is directly implicated in the pathophysiology of this subset of preterm labor/birth. However, the underlying etiologies leading to reduced Tregs, such as dysregulation of the vaginal microbiome ([@R31]; [@R36]) or intestinal microbiome ([@R126]), require further investigation.

In searching for the mechanisms implicated in this model of idiopathic preterm labor/birth, we found that the depletion of Tregs induced elevated concentrations of CCL7, IL-22, and IFNγ in the maternal circulation. However, only systemic administration of CCL7 and IL-22 at pathological concentrations shortened the length of gestation, inducing early-term delivery. Previous clinical reports have shown that CCL7 ([@R76]) and IL-22 ([@R10]) are slightly increased in women with preterm labor and preeclampsia, respectively. Furthermore, the administration of IL-22 reduces Tregs and increases alloreactive Teffs ([@R154]). Hence, we propose that the depletion of Tregs shortens the length of gestation by increasing these inflammatory cytokines in the maternal circulation, even though neither the individual nor the combined systemic effects of these cytokines can entirely explain the pathophysiology of preterm birth resulting from the loss of Tregs.

Further investigation revealed that the depletion of Tregs altered specific cellular responses in the maternal circulation, at the maternal-fetal interface, and in the placenta. Overall, Treg depletion increased the abundance of pro-inflammatory immune cells such as B cells ([@R83]) and neutrophils ([@R8]) expressing TNF-α and reduced homeostatic immune cells such as arginase 1-expressing neutrophils ([@R87]). As expected, IL-10- and TGF-β-expressing CD4+ T cells (i.e., Tregs) were also reduced. Therefore, it is tempting to suggest that Tregs play a central role during late pregnancy in modulating systemic and local cellular responses and that their absence can cause a pro-inflammatory environment, leading to preterm birth.

Importantly, fetuses of Treg-depleted dams exhibited signs of fetal growth restriction, which allowed us to hypothesize that the loss of maternal Tregs causes alterations in placental development. In line with this hypothesis, we found that several key biological processes primarily related to embryo development and cellular metabolic processes were dysregulated in the placental tissues upon Treg depletion. These findings are consistent with previous reports showing that Tregs participate in the development and function of the placenta ([@R67]; [@R121]; [@R81]; [@R88], [@R89]; [@R15]). Recently, it was shown that the adoptive transfer of uterine-like NK cells can serve as a treatment for growth-restricted fetuses ([@R39]), suggesting that Tregs and NK cells may contribute to the development of offspring.

We also showed that the deleterious effects of Treg depletion on the placenta were carried over to neonatal life, given that a subset of neonates born to Treg-depleted dams died before weaning age. This finding is consistent with clinical studies showing that newborns with growth restriction have fewer cord blood Tregs ([@R134]; [@R86]). Herein, we also found that adverse neonatal outcomes were more prevalent when Tregs were depleted in repeat pregnancies, supporting the concept that pregnancy imprints protective regulatory memory ([@R117]) and that the resulting enhanced Treg expansion in a second pregnancy is involved not only in maternal-fetal tolerance but also in neonatal well-being. Lastly, we provided a causal link between neonatal mortality and Treg depletion since the adoptive transfer of these cells mitigated adverse perinatal outcomes.

In summary, we have shown that a subset of women with idiopathic PTL and birth, formerly considered to have an unknown cause, is associated with a reduction of functional Tregs at the maternal-fetal interface. This finding is in tandem with clinical reports showing that women who underwent preterm labor and birth have reduced numbers and function of Tregs in the maternal circulation ([@R146]; [@R123]). Consistently, the systemic deficiency of Tregs results in a fraction of preterm births in first and repeat pregnancies and, more importantly, induces adverse outcomes in offspring. The mechanisms whereby the loss of Tregs induces adverse perinatal outcomes involve alterations in cellular and soluble immune responses in the mother and at the maternal-fetal interface, as well as dysregulation of developmental and cellular processes in the placenta. This study provides insight into the mechanisms of disease for idiopathic PTL and birth, the leading cause of neonatal morbidity and mortality worldwide.
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### Lead Contact {#S18}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Nardhy Gomez-Lopez (<nardhy.gomez-lopez@wayne.edu>).

### Materials Availability {#S19}

This study did not generate new unique reagents.

### Data and Code Availability {#S20}

The accession number for the RNA-seq data reported in this paper is GEO: GSE145357.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S21}
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### Human subjects, clinical specimens, and definitions {#S22}

Human placental basal plate (decidua basalis) and chorioamniotic membrane (decidua parietalis) samples were obtained at the Perinatology Research Branch, an intramural program of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD), National Institutes of Health, U.S. Department of Health and Human Services, Wayne State University (Detroit, MI, USA), and the Detroit Medical Center (Detroit, MI, USA). The collection and use of human materials for research purposes were approved by the Institutional Review Boards of NICHD and Wayne State University. All participating women provided written informed consent prior to sample collection. The study groups included women who delivered at term with labor/birth (TIL), at term without labor (TNL), preterm with labor (PTL), or preterm without labor (PTNL). Patients with PTL were further categorized into those who underwent idiopathic preterm labor/birth without inflammation (iPTL), those with idiopathic preterm labor/birth with chronic inflammatory lesions of the placenta (iPTL+CI), and those with preterm labor/birth with acute inflammatory lesions of the placenta (PTL+AI). Patients with TIL were further categorized into those who underwent term labor without inflammation (TIL), those with chronic inflammatory lesions of the placenta (TIL+CI), and those with acute inflammatory lesions of the placenta (TIL+AI). The demographic and clinical characteristics of the study groups are shown in [Tables S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}. Labor was defined by the presence of regular uterine contractions at a frequency of at least two contractions every 10 min with cervical changes resulting in delivery. Preterm delivery was defined as delivery \< 37 weeks of gestation. Patients with multiple births or neonates that had congenital or chromosomal abnormalities were excluded from this study.

### Placental histopathological examination {#S23}

Placentas were examined histologically by a perinatal pathologist blinded to clinical diagnoses and obstetrical outcomes according to standardized Perinatology Research Branch protocols. Briefly, three to nine sections of the placenta were examined, and at least one full-thickness section was taken from the center of the placenta; others were taken randomly from the placental disc. Chronic and acute inflammatory lesions of the placenta were diagnosed following established Perinatology Research Branch protocols ([@R104], [@R102], [@R73], [@R74]).

### Mice {#S24}

B6.129(Cg)-Foxp3^*tm3(DTR/GFP)Ayr*^ (*Foxp3*^*DTR*^), BALB/cBy (BALB/c), C57BL/6-Tg (CAG-EGFP)131Osb/LeySopJ (*EGFP*), and C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were bred in the animal care facility at the C.S. Mott Center for Human Growth and Development (Wayne State University, Detroit, MI, USA) and housed under a circadian cycle (light:-dark = 12:12 h). Eight- to twelve-week-old *Foxp3*^*DTR*^, *EGFP*, or C57BL/6 females were mated with BALB/c or C57BL/6 males of proven fertility. Female mice were examined daily between 8:00 and 9:00 a.m. for the presence of a vaginal plug, which indicated 0.5 days *post coitum* (dpc). After observation of vaginal plugs, female mice were removed from the mating cages and housed separately. A weight gain ≥2 g confirmed pregnancy at 12.5 dpc. All animal experiments were approved by the Institutional Animal Care and Use Committee at Wayne State University (Protocol No: A-09-08-12, A-07-03-15 and 18-03-0584).

METHOD DETAILS {#S25}
--------------

### Decidual leukocyte isolation from human samples {#S26}

Leukocytes were isolated from human decidual tissue ([Table S2](#SD1){ref-type="supplementary-material"}) as previously described ([@R147]). Briefly, the decidua basalis was collected from the basal plate of the placenta, and the decidua parietalis was separated from the chorioamniotic membranes. Decidual tissue was homogenized using a gentleMACS Dissociator (Miltenyi Biotec, San Diego, CA, USA) in StemPro Cell Dissociation Reagent (Life Technologies, Grand Island, NY, USA). Homogenized tissues were incubated for 45 min at 37°C with gentle agitation. After incubation, tissues were washed with 1X PBS (Life Technologies) and filtered through a 100 μm cell strainer. Cell suspensions were collected and centrifuged at 300 × g for 10 min at 4°C, and the cell pellet was suspended in stain buffer (BD Biosciences, San Jose, CA, USA). Mononuclear cells were purified using a density gradient (Ficoll-Paque Plus; GE Healthcare Bio-Sciences, Up-psala, Sweden), following the manufacturer's instructions. Then, mononuclear cell suspensions were washed using stain buffer prior to immunophenotyping.

### Immunophenotyping of human decidual leukocytes {#S27}

Mononuclear cell suspensions were washed with stain buffer and centrifuged. Cell pellets were incubated for 10 min at 4°C with 20 μL of human FcR Blocking Reagent (Miltenyi Biotec) in 80 μL of stain buffer. Next, mononuclear cell suspensions were incubated with extracellular fluorochrome-conjugated anti-human mAbs ([Key Resources Table](#T1){ref-type="table"}) for 30 min at 4°C in the dark. After extracellular staining, the cells were fixed. For intracellular staining, the cells were fixed and permeabilized using the Foxp3/Transcription Factor Fixation/Permeabilization solution (eBioscience) prior to incubation with intracellular anti-human mAbs ([Key Resources Table](#T1){ref-type="table"}). Finally, mononuclear cell suspensions were washed and resuspended in 0.5 mL of stain buffer and acquired using the BD LSR Fortessa flow cytometer and FACSDiva 6.0 software. Flow cytometry analysis was performed using the FlowJo software v10 (FlowJo, Ashland, OR, USA).

### Human Treg suppression assays {#S28}

Decidual leukocytes were isolated from the decidual basalis from women who delivered preterm or at term ([Table S1](#SD1){ref-type="supplementary-material"}), as described above. Leukocytes were incubated with BD Horizon Fixable Viability Stain 510 for 30 min at 4°C, then washed with 1X PBS. The cells were resuspended in stain buffer and incubated with fluorochrome conjugated anti-human mAbs ([Key Resources Table](#T1){ref-type="table"}) for 30 min at 4°C in the dark. The cells were washed with 1X PBS to remove excess antibody, resuspended in 0.5 mL of presort buffer (BD Bio-sciences), and effector T cells (Teff cells; CD45+CD3+CD4+CD25cells) and regulatory T cells (Tregs; CD45+CD3+CD4+CD25+CD127low cells) were sorted using the BD FACSMelody cell sorter (BD Biosciences) and BD FACSChorus version 1.3 software (BD Biosciences). The expression of Foxp3 by sorted Tregs was confirmed by flow cytometry using the BD LSR Fortessa flow cytometer and FACSDiva 6.0 software.

Sorted Tregs were resuspended in RPMI media (Thermo Fisher Scientific, Grand Island, NY, USA) supplemented with 10% FBS and 1% penicillin/streptomycin (Thermo Fisher Scientific) at 4×10^4^ cells/mL. Purified CD4+CD25-Teff cells were labeled with the CellTrace Violet Cell Proliferation Kit (Molecular Probes, Eugene, OR, USA), following the manufacturer's instructions. Labeled Teff cells were adjusted to 4×10^4^ cells/mL in supplemented RPMI medium. The Tregs and Teff cells were co-cultured in a round-bottom 96-well plate at a ratio of 1:1, 1:2, 1:4, and 1:8, respectively. Dynabeads Human T-Activator CD3/CD28 were added to the co-culture to obtain a bead:cell ratio of 1:1. The culture plate was then incubated at 37°C with 5% CO~2~ for 96 h. Human recombinant IL-2 (30 U/mL; Thermo Fisher Scientific) was used to stimulate T cell expansion, and 2-mercaptoethanol (55 μM; Thermo Fisher Scientific) was added to maintain cell viability. The suppressive capacity of Treg cells was determined using flow cytometry to analyze the proliferation of Teff cells under different co-culture conditions, according to the CellTrace Violet fluorescence intensity of the Teff cells. The percentage of Treg suppression of Teff cell expansion was calculated using the following formula: percentage of suppression = \[(Number of proliferated Teff cells cultured alone -- Number of proliferated Teff cells co-cultured with Tregs)/Number proliferated Teff cells cultured alone\] × 100.

### Treg suppression assays in the second and third week of murine pregnancy {#S29}

C57BL/6 female mice were mated with BALB/c males as described above. Dams were sacrificed either in the 2^nd^ week (10.5--13.5 dpc) or 3^rd^ week (16.5 dpc) of pregnancy and the spleens were harvested. Splenocytes were isolated from the spleen as previously described ([@R5]), filtered through a 30 μm cell strainer (Miltenyi Biotec), and washed with sterile 1X PBS. Splenocytes were counted using an automatic cell counter (Cellometer Auto 2000; Nexcelom, Lawrence, MA, USA) to obtain a preliminary cell number for Treg isolation. Approximately 1×10^8^ splenocytes were taken for Treg isolation using the mouse CD4+CD25+ Regulatory T cell Isolation Kit (Miltenyi Biotec), following the manufacturer's instructions. The counts of isolated Tregs (CD3+CD4+CD25+Foxp3+ cells) and Teff (CD3+CD4+CD25-cells) cells were determined by flow cytometry, using CountBright Absolute Counting Beads (Molecular Probes).

Purified Tregs were adjusted to 5×10^5^ cells/mL in supplemented RPMI. Purified Teff cells were labeled with the CellTrace Violet Cell Proliferation Kit, following the manufacturer's instructions. Labeled Teff cells were adjusted to 5×10^5^ cells/mL in supplemented RPMI medium. The Tregs and Teff cells were co-cultured in a round-bottom 96-well plate at a ratio of 1:1, 1:2, 1:4, and 1:8, respectively, and cultured with CD3/CD28-loaded MACSiBeads (5×10^5^ beads/mL), mouse recombinant IL-2 (200 U/mL; Miltenyi Biotec), and 2-mercaptoethanol (55mM). The culture plate was then incubated at 37°C with 5% CO~2~ for 96 h. The suppressive capacity of Tregs was determined using flow cytometry to analyze the proliferation of Teff cells under different co-culture conditions, according to the CellTrace Violet fluorescence intensity of the Teff cells. Dead cells were excluded using the Live/Dead Fixable Green Dead Cell Stain Kit (Molecular Probes). The percentage of Treg suppression of Teff cell expansion was calculated using the following formula: percentage of suppression = \[(Number of proliferated Teff cells cultured alone -- Number of proliferated Teff cells co-cultured with Tregs)/Number proliferated Teff cells cultured alone\] × 100.

### Depletion of Tregs in non-pregnant mice and leukocyte isolation from lymphatic tissues {#S30}

Naive non-pregnant *Foxp3*^*DTR*^ mice were injected intraperitoneally (i.p.) with 25 μg/kg (partial depletion of Tregs) or 50 μg/kg (total depletion of Tregs) of diphtheria toxin from *Corynebacterium diphtheria* (DT; Sigma-Aldrich, St. Louis, MO, USA; Calbiochem, EMD Millipore Corp, Billerica, MA, USA; or Enzo Life Sciences, Inc., Farmingdale, NY, USA) in 200 μL of sterile 1X PBS (Fisher Scientific, Fair Lawn, NY, USA) or with 200 μL sterile 1X PBS using a 26-gauge needle. Twenty-four hours post-injection, mice received a second injection of 25 or 50 μg/kg of DT, respectively, in 200 μL of sterile 1X PBS, or with 200 μL sterile 1X PBS. Four hours later, the uterine-draining lymph nodes (ULN), spleen, and thymus were collected and leukocyte suspensions were prepared as previously reported ([@R5]) to determine the proportion of Tregs (CD3+CD4+CD25+Foxp3+ cells) by flow cytometry.

### Depletion of Tregs in pregnant mice {#S31}

*Foxp3*^*DTR*^ dams were injected i.p. with 25 μg/kg of DT ([@R116], [@R117]) (partial depletion of Tregs) or 50 μg/kg of DT ([@R70], [@R121]) (total depletion of Tregs) dissolved in 200 μL of sterile 1X PBS using a 26-gauge needle on 14.5 dpc. Controls were injected with 200 μL of sterile 1X PBS alone. After 24 h, dams were injected with 5 μg/kg of DT or 50 μg/kg of DT, respectively, in 200 μL of sterile 1X PBS, or with 200 μL of sterile 1X PBS alone. Four hours later, dams were euthanized and the decidual, myometrial, placental, and lymphatic tissues were collected, as well as the peripheral blood, to determine the proportion of Tregs by flow cytometry.

### Leukocyte isolation from murine decidua, myometrium, placenta, lymphatic tissues, and peripheral blood to verify Treg depletion {#S32}

Isolation of leukocytes from decidual, myometrial, and placental tissues was performed as previously described ([@R4]). Briefly, tissues were minced into small pieces using fine scissors and enzymatically digested with StemPro Cell Dissociation Reagent for 35 minutes at 37°C. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient using Ficoll-Paque Plus and washed with 1X PBS. The uterine-draining lymph nodes (ULN), inguinal lymph nodes (ILN), mesenteric lymph nodes (MLN), spleen, and thymus were also collected and leukocyte suspensions were prepared, as previously reported ([@R5]). Leukocytes were filtered using a 100 μm cell strainer and washed with FACS buffer \[0.1% BSA (Sigma-Aldrich) and 0.05% sodium azide (Fisher Scientific Chemicals) in 1X PBS)\] before immunophenotyping.

Leukocyte suspensions prepared from the decidua, myometrium, placenta, lymphatic tissues, and peripheral blood were centrifuged at 1,250 × g for 10 min at 4°C in the dark. Cells were stained with the Live/Dead Fixable Green Dead Cell Stain Kit for 10 min at 4°C in the dark, followed by washing with 1X PBS. Cell pellets were then incubated with the CD16/CD32 mAb (FcγIII/II receptor; BD Biosciences) for 10 min and subsequently incubated with specific fluorochrome-conjugated anti-mouse mAbs ([Key Resources Table](#T1){ref-type="table"}) for 30 min at 4°C in the dark. Leukocyte suspensions were fixed/permeabilized with the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) prior to staining with intranuclear anti-mouse mAbs. Cells were acquired for determination of Tregs (CD3+CD4+CD25+Foxp3+ cells) using the BD LSR Fortessa flow cytometer and FACSDiva 6.0 software. Data were analyzed using FlowJo software v10.

### Animal models of Treg depletion and preterm birth in the first and second pregnancy {#S33}

Partial depletion (25 μg/kg) or total depletion (50 μg/kg) of Tregs was performed in *Foxp3*^*DTR*^ dams as described above, and secondary injections (5 μg/kg or 50 μg/kg, respectively) were repeated every 24 h until delivery. Control dams were injected with 200 μL of sterile 1X PBS. Following injection, dams were monitored by infrared camera (Sony, Tokyo, Japan) until delivery. Gestational length was calculated from the presence of the vaginal plug until the appearance of the first pup in the cage bedding. Preterm birth was defined as delivery of all pups \< 18.5 dpc. Neonatal survival and weights were recorded at birth and 1, 2, and 3 weeks postpartum. Photographs of neonates were also taken on the day of birth to verify breastfeeding. After 3 weeks of observation, dams were returned to mating cages to undergo a second pregnancy, underwent partial or total Treg depletion (or PBS injection) as described above, and were again monitored to determine pregnancy and neonatal outcomes until 3 weeks postpartum.

### Fetal and placental weights from Treg-depleted dams {#S34}

*Foxp3*^*DTR*^ dams were injected with 25 or 50 μg/kg of DT dissolved in 200 μL of sterile 1X PBS, or 200 μL of sterile 1X PBS alone, on 14.5 dpc. Twenty-four hours after injection, dams were injected with 5 or 50 μg/kg of DT dissolved in 200 μL of sterile 1X PBS, or 200 μL of sterile 1X PBS alone, respectively. Four hours later, dams were euthanized and the fetal and placental weights were measured using a scale (DIA-20; American Weights Scales, Norcross, GA, USA). Photographs of the fetuses and placentas were also taken.

### Cell sorting and adoptive transfer of Tregs {#S35}

Splenic Tregs were isolated from C57BL/6 dams at 10.5--13.5 dpc. Tregs were isolated using the mouse CD4+CD25+ Regulatory T Cell Isolation Kit, according to the manufacturer's instructions. The isolated Tregs were characterized (CD3+CD4+CD25+Foxp3+ cells) and quantified by flow cytometry prior to injection. *Foxp3*^*DTR*^ dams were injected intravenously with 1×10^5^ -- 1×10^6^ Tregs/100 μL of sterile 1X PBS on 14.5 and 16.5 dpc. Two hours after the initial adoptive transfer, dams were i.p injected with 25 μg/kg of DT diluted in 200 μL of sterile 1X PBS. After 24 h, dams were injected with 5 μg/kg of DT diluted in 200 μL of sterile 1X PBS, which was repeated every 24 h until delivery. Following the second adoptive transfer, dams were monitored by infrared camera until delivery to record the rates of preterm birth and neonatal survival at birth. Neonatal survival was recorded at birth and 1, 2, and 3 weeks postpartum.

To determine the proportion of adoptively transferred Tregs present in peripheral and reproductive tissues, splenic Tregs were isolated from *EGFP* dams at 10.5--13.5 dpc. Tregs were isolated using the mouse CD4+CD25+ Regulatory T Cell Isolation Kit, according to the manufacturer's instructions. The isolated Tregs were characterized (CD3+CD4+CD25+Foxp3+ cells) and quantified by flow cytometry prior to injection. *Foxp3*^*DTR*^ dams were injected intravenously with 1×10^5^ -- 1×10^6^ Tregs/100 μL of sterile 1X PBS on 14.5 and 16.5 dpc. Two hours after the initial adoptive transfer, dams were i.p injected with 25 μg/kg of DT diluted in 200 μL of sterile 1X PBS. After 24 h, dams were injected with 5 μg/kg of DT diluted in 200 μL of sterile 1X PBS, which was repeated until 17.5 dpc. On 18.5 dpc, dams were euthanized and the decidual, myometrial, and placental tissues were collected, as well as the peripheral blood and lymphatic tissues. Leukocyte isolation and immunophenotyping of Tregs was performed as described above to determine the proportion of adoptively transferred Tregs present in each tissue.

### Measurement of maternal-fetal obstetrical parameters {#S36}

Partial depletion (25 μg/kg) or total depletion (50 μg/kg) of Tregs was performed in *Foxp3*^*DTR*^ dams as described above, and secondary injections (5 μg/kg or 50 μg/kg, respectively) were repeated every 24 h until 17.5 dpc. Control dams were injected with 200 μL of sterile 1X PBS. On 17.5 dpc, three hours after injection, body temperature was evaluated using a rectal probe (TMH-150; VisualSonics Inc., Toronto, ON, Canada). Next, dams were placed in a restrainer and the arterial blood pressure was measured in the tail using a non-invasive method, according to manufacturer's instructions (Noninvasive Blood Pressure System, CODA High Throughput System; Kent Scientific Corporation, Torrington, CT, USA). The systolic, diastolic, and mean pressures were registered. Afterward, dams were anesthetized by inhalation of 2%--3% isoflurane (Aerrane; Baxter Healthcare Corporation, Deerfield, IL, USA) and 1--2 L/min of oxygen in an induction chamber. Anesthesia was maintained with a mixture of 1.75%--2% isoflurane and 2.0 L/min of oxygen during the ultrasound procedure, which was performed using the Vevo 2100 Imaging System (VisualSonics Inc.) as previously described ([@R133], [@R49], [@R6]). Three fetuses from each dam were evaluated, including the first fetus in each uterine horn. The fetal and maternal heart rates and the pulsatility indices (PI) were examined in the right and left uterine arteries as well as in the umbilical artery using the 55-MHz linear ultrasound probe (VisualSonics Inc.). The PI was calculated using the following formula: \[PI = (peak systolic velocity -- end diastolic velocity)/mean velocity\]. Ultrasound signals were processed, displayed, and stored using the Vevo Imaging Station (VisualSonics Inc.). Following the ultrasound procedure, dams were euthanized and photographs of the maternal spleen and ULN were taken.

### Model of susceptibility to endotoxin-induced preterm birth after Treg depletion {#S37}

*Foxp3*^*DTR*^ dams were injected i.p. with an initial dose of 25 μg/kg of DT diluted in 200 μL of sterile 1X PBS on 14.5dpc. Twenty-four hours post-injection, dams received a second injection of 25 μg/kg of DT diluted in 200 μL of sterile 1X PBS. On 16.5 dpc, *Foxp3*^*DTR*^ dams were injected with 2 μg/200 μL of lipopolysaccharide (LPS) from *Escherichia coli* (O55:B5; Sigma-Aldrich). Non-Treg-depleted control *Foxp3*^*DTR*^ dams were injected with sterile 1X PBS on 14.5 and 15.5 dpc and 2 μg/200 μL of LPS on 16.5 dpc. Controls also included *Foxp3*^*DTR*^ dams injected with DT only on 14.5 and 15.5 dpc. Following injection, dams were monitored by infrared camera until delivery to record the rates of preterm birth. Neonatal survival was recorded at birth and 1, 2, and 3 weeks postpartum.

### Determination of cytokine concentrations in the maternal circulation and amniotic fluid {#S38}

*Foxp3*^*DTR*^ dams were injected with 25 or 50 μg/kg of DT dissolved in 200 μL of sterile 1X PBS, or 200 μL of sterile 1X PBS alone, on 14.5dpc. Twenty-four hours after injection, dams were injected with 5 or 50 μg/kg of DT, respectively, dissolved in 200 μL of sterile 1X PBS, or 200 μL of sterile 1X PBS alone. Four hours later, dams were euthanized and peripheral blood was collected by cardiac puncture for plasma separation. Amniotic fluid was also obtained from each amniotic sac with a 26-gauge needle. To determine the cytokine storm in endotoxin-induced preterm birth, C57BL/6 dams were i.p. injected with 10 μg of LPS dissolved in 200 μL of sterile 1X PBS on 16.5 dpc. Dams were euthanized on 17.5 dpc and peripheral blood was collected by cardiac puncture for plasma separation. Maternal plasma and amniotic fluid samples were centrifuged at 800 or 1300 × g, respectively, for 10 min at 4°C and the supernatants were separated and stored at −20°C until analysis. The ProcartaPlex Mouse Cytokine & Chemokine Panel 1A 36-plex (Invitrogen by Thermo Fisher Scientific, Vienna, Austria) was used to measure the concentrations of IFNγ, IFNα, IL-12p70, IL-1β, TNFα, GM-CSF, IL-18, IL-17A, IL-22, IL-23, IL-27, IL-9, IL-15/IL-15R, IL-13, IL-2, IL-4, IL-5, IL-6, IL-10, CCL11, IL-28, IL-3, LIF, IL-1α, IL-31, CXCL1, CCL3, CXCL10, CCL2, CCL7, CCL4, CXCL2, CCL5, G-CSF, M-CSF, and CXCL5 in maternal plasma and amniotic fluid samples, according to the manufacturer's instructions. Plates were read using the FLEXMAP 3D (Luminex Corporation, Austin, TX, USA), and analyte concentrations were calculated with ProcartaPlex Analyst 1.0 Software from Affymetrix, San Diego, CA, USA. The sensitivities of the assays were: 0.09 pg/mL (IFNγ), 3.03 pg/mL (IFNα), 0.21 pg/mL (IL-12p70), 0.14 pg/mL (IL-1β), 0.39 pg/mL (TNFα), 0.19 pg/mL (GM-CSF), 9.95 pg/mL (IL-18), 0.08 pg/mL (IL-17A), 0.24 pg/mL (IL-22), 2.21 pg/mL (IL-23), 0.34 pg/mL (IL-27), 0.28 pg/mL (IL-9), 0.42 pg/mL (IL-15/IL-15R), 0.16 pg/mL (IL-13), 0.10 pg/mL (IL-2), 0.03 pg/mL (IL-4), 0.32 pg/mL (IL-5), 0.21 pg/mL (IL-6), 0.69 pg/ mL (IL-10), 0.01 pg/mL (CCL11), 20.31 pg/mL (IL-28), 0.11 pg/mL (IL-3), 0.28 pg/mL (LIF), 0.32 pg/mL (IL-1α), 0.45 pg/mL (IL-31), 0.05 pg/mL (CXCL1), 0.13 pg/mL (CCL3), 0.26 pg/mL (CXCL10), 3.43 pg/mL (CCL2), 0.15 pg/mL (CCL7), 1.16 pg/mL (CCL4), 0.37 pg/mL (CXCL2), 0.35 pg/mL (CCL5), 0.19 pg/mL (G-CSF), 0.02 pg/mL (M-CSF), and 5.67 pg/mL (CXCL5). Inter-assay and intra-assay co-efficients of variation were less than 10%. Amniotic fluid cytokine concentrations were adjusted by protein concentration, which were determined using the Pierce BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA), following the manufacturer's instructions.

### Systemic injection of cytokines/chemokines in pregnant mice {#S39}

C57BL/6 dams were intravenously injected with 1.4 pg of recombinant mouse IFNγ (Peprotech, Rocky Hill, NJ, USA), 218 pg of recombinant mouse CCL7 (R&D Systems, Minneapolis, MN, USA), or 48 pg of recombinant mouse IL-22 (Biolegend, San Diego, CA, USA), or a combination of these three cytokines, dissolved in 100 μL of sterile 1X PBS using a 26-gauge needle on 15.5, 16.5, and 17.5 dpc. Controls were injected with 100μL of sterile 1X PBS alone. Following injection, dams were monitored by infrared camera until delivery to record the rates of full or early term birth and neonatal mortality at birth, and neonates were monitored for up to 3 weeks after delivery.

### Immunophenotyping of leukocytes from the decidual, myometrial, and placental tissues and peripheral blood {#S40}

*Foxp3*^*DTR*^ dams were injected with 25 or 50 μg/kg of DT dissolved in 200 μL of sterile 1X PBS, or 200 μL of sterile 1X PBS alone, on 14.5dpc. Twenty-four hours after injection, dams were injected with 5 or 50 μg/kg of DT, respectively, dissolved in 200 μL of sterile 1X PBS, or 200 μL of sterile 1X PBS alone. Four hours later, dams were euthanized and the decidual, myometrial, and placental tissues, as well as the peripheral blood, were collected. The PBMCs were isolated from peripheral blood by density gradient using Ficoll-Paque Plus and washed with 1X PBS. Leukocyte suspensions were prepared from decidual, myometrial, and placental tissues as previously described ([@R4]), and were stained using the BD Fixable Viability Stain 510 prior to incubation with anti-mouse mAbs ([Key Resources Table](#T1){ref-type="table"}). Leukocyte suspensions were centrifuged at 1,250 × g for 10 min at 4°C in the dark. Cells were then incubated with the CD16/CD32 mAb (FcγIII/II receptor) for 10 min and subsequently incubated with specific fluorochrome conjugated anti-mouse mAbs ([Key Resources Table](#T1){ref-type="table"}) for 30 min at 4°C in the dark. Leukocyte suspensions were fixed/permeabilized with the BD Cytofix/Cytoperm Fixation/Permeabilization Kit or Foxp3/Transcription Factor Staining Buffer Set prior to straining with intracellular or intranuclear anti-mouse mAbs. Cells were acquired using the BD LSR Fortessa flow cytometer and FACSDiva 6.0 software. Immunophenotyping included the identification of macrophages (CD45+CD11b+F4/80+Ly6G-cells), neutrophils (CD45+CD11b+F4/80-Ly6G+ cells), dendritic cells (DCs; CD45+CD11b+F4/80-CD11c+CD205+ cells), NK cells (CD45+CD11b-CD49b+ cells), T cells (CD3+ cells), CD4+ T cells (CD3+CD4+ cells), CD8+ T cells (CD3+CD8+ cells), and B cells (CD45+CD11b-CD19+ cells) in the decidual, myometrial, and placental tissues as well as in the maternal circulation. The activation status of these cells was determined by cytokine expression ([Key Resources Table](#T1){ref-type="table"}). Data were analyzed using FlowJo software v10. Log2 fold changes in cell abundance (frequencies) were determined and represented in heatmaps.

### RNA-seq analysis of placental tissues {#S41}

#### RNA isolation, library preparation, and sequencing: {#S42}

Partial depletion (25 μg/kg) or total depletion (50 μg/kg) of Tregs was performed in *Foxp3*^*DTR*^ dams on 14.5 dpc as described above, and secondary injections (5 μg/kg or 50 μg/kg, respectively) were performed 24 h after (15.5 dpc). Four hours later, dams were euthanized and the placental tissues were collected from implantation sites and placed in RNA*later* Stabilization Solution (Life Technologies). Total RNA was isolated from tissues using the RNeasy mini kit (QIAGEN, Hilden, Germany), following the manufacturer's instructions. RNA concentrations and purity were assessed with the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific), and RNA integrity was evaluated with the 2100 Bioanalyzer system (Agilent Technologies, Wilmington, DE) using the Agilent RNA 6000 Nano Kit (Agilent Technologies). The RNA-Seq library was prepared by the Beijing Genomics Institute (BGI; Wuhan, China) using the MGIEasy RNA Library Prep kit (MGI Americas Inc., San Jose, CA, USA). Paired-end reads of 150 bp length were sequenced on the BGISEQ-500RS sequencer (BGI), and raw data were provided by BGI.

#### Pre-processing of RNA-Seq data: {#S43}

Paired-end RNA-Seq sequence data in *fastq* format were processed using Salmon aligner v0.12.0 ([@R95]) in quasi-mapping mode using a transcriptome index prepared from *Mus musculus* genome assembly *GRCm38* (mm10). Transcripts per million (TPM) values from Salmon output were scaled up to library size and imported into R (version 3.5.2) using the *tximport* package of Bioconductor ([@R41], [@R130]).

#### Assessment of differences between treatment groups: {#S44}

Count data were analyzed using negative binomial models implemented in the *DESeq2* package ([@R2]). Only genes that had counts \> 5 in at least five samples were retained for further analysis. Genes were considered to be differentially expressed if the fold change between groups was \> 1.25 and the false discovery rate ([@R9]) adjusted p value was \< 0.1.

#### RNA-Seq data visualization: {#S45}

The RNA-Seq data (log2 counts) for the top 50 upregulated and top 50 downregulated genes were visualized using heatmaps with hierarchical clustering of genes.

#### Biological process determination: {#S46}

Over-representation of biological processes among significantly up- and down- regulated genes was determined separately by performing hypergeometric tests using the stringApp v1.5.0 ([@R29]) in Cytoscape v3.7.2 ([@R92]). The stringApp was also used to visualize known interactions between proteins coded by the differentially expressed genes in selected biological processes. Over-representation of biological processes among all differentially expressed genes, regardless of their direction of change, was also tested with ClueGO v2.5.5 ([@R85]) and the significantly disrupted biological processes were grouped based on their functional annotation and visualized as a network of gene ontologies. A q-value cutoff of \< 0.05 was used to determine significance of enrichment analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S47}
---------------------------------------

### Statistical Analysis {#S48}

Statistical analyses were performed using SPSS v19.0 (IBM, Armonk, NY, USA) or the R package (version 3.5.2). For human demographic data, the group comparisons were performed using the Fisher's test with Monte-Carlo simulation for proportions and Kruskal-Wallis tests for non-normally distributed continuous variables. The Mann-Whitney U-test was used to compare differences between the groups for human flow cytometry data. The Fisher's exact test was used to compare the rates of preterm birth. The Kaplan-Meier survival curves were used to plot and compare the neonatal survival data (Mantel-Cox test). The Kruskal-Wallis and ANOVA tests were utilized for comparisons among groups for murine observational and obstetrical data as well as for maternal plasma and amniotic fluid cytokine concentrations. A p value % 0.05 was considered statistically significant. For flow cytometry heatmaps, the statistical significance of differences between study groups were assessed using t tests followed by the false discovery rate adjustment of p values, with a q \< 0.1 being considered significant (represented as asterisks in the heatmap). RNA-Seq analysis was performed as described above.
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![Functional Tregs Are Reduced at the Human Maternal-Fetal Interface in a Subset of Idiopathic PTL and birth\
(A) Representative gating strategy used to sort Tregs and Teffs from the decidua. Tregs were co-cultured with Teffs, and Teff proliferation was measured by flow cytometry using CellTrace violet.\
(B) Representative plots showing the proliferation of Teffs, with the percentage of decidual Treg suppression of Teffs from preterm and term pregnancies. Suppression data are shown as means ± SEM. n = 6--8 per group.\
(C) Representative gating strategy used to identify Tregs in the decidua parietalis and decidua basalis.\
(D and E) Frequency of Tregs in the (D) decidua parietalis (n = 11--28 per group) or (E) decidua basalis (n = 13--28 per group) of women with PTNL, iPTL, iPTL+CI, or PTL+AI.\
(F and G) Frequency of Tregs in the (F) decidua parietalis (n = 13--19 per group) or (G) decidua basalis (n = 13--19 per group) of women with TNL, TIL, TIL+CI, or TIL+AI.\
Data are represented as medians with interquartile and minimum/maximum ranges. Statistical analysis was performed using the Mann-Whitney U-test. Demographic and clinical characteristics of the study population are shown in [Tables S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1610265-f0002){#F1}

![Tc17 Cells Are Increased at the Human Maternal-Fetal Interface in Idiopathic PTL and birth\
(A) Representative gating strategy used to identify Th17 cells and Tc17 cells in the decidua parietalis and decidua basalis.\
(B and C) Frequency of Th17 cells in the (B) decidua parietalis (n = 11--28 per group) or (C) decidua basalis (n = 13--28 per group) of women with PTNL, iPTL, iPTL+CI, or PTL+AI.\
(D and E) Frequency of Th17 cells in the (D) decidua parietalis (n = 13--19 per group) or (E) decidua basalis (n = 13--19 per group) of women with TNL, TIL, TIL+CI, or TIL+AI.\
(F and G) Frequency of Tc17 cells in the (F) decidua parietalis (n = 11--28 per group) or (G) decidua basalis (n = 13--28 per group) of women with PTNL, iPTL, iPTL+CI, or PTL+AI.\
(H and I) Frequency of Tc17 cells in the (H) decidua parietalis (n = 13--19 per group) or (I) decidua basalis (n = 13--19 per group) of women with TNL, TIL, TIL+CI, or TIL+AI.\
Data are represented as medians with interquartile and minimum/maximum ranges. Statistical analysis was performed using the Mann-Whitney U-test. Demographic and clinical characteristics of the study population are shown in [Table S2](#SD1){ref-type="supplementary-material"}.](nihms-1610265-f0003){#F2}

![Depletion of Tregs Induces a Fraction of Preterm Births and Adverse Neonatal Outcomes\
(A) *Foxp3*^*DTR*^ dams underwent partial or total Treg depletion. Controls were injected with sterile 13 PBS. After the first pregnancy (P), a subset of *Foxp3*^*DTR*^ dams underwent a second P and were again partially or totally Treg-depleted or were injected with sterile 13 PBS.\
(B) Frequencies of Tregs in the decidua, myometrium, peripheral blood, and placenta of partially or totally Treg-depleted *Foxp3*^*DTR*^ dams (n = 5--7 per group). Data are represented as medians with interquartile and minimum/maximum ranges.\
(C) Preterm birth rates of non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (1^st^ or 2^nd^ P, n = 9--20 per group). Data are represented as means of percentages.\
(D) Percentage of survival from birth until 3 weeks postpartum for neonates born to non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (1^st^ or 2^nd^ P, n = 7--18 per group).\
(E--G) Weights of neonates born to non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams at weeks (E) 1, (F) 2, and (G) 3 postpartum (1^st^ or 2^nd^ P, n = 2--12 litters per group). Data are represented as violin plots with medians and minimum/maximum ranges.\
(H) Representative images of fetuses (and their placentas) from non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (n = 8--9 per group).\
(I and J) Weights of (I) fetuses and (J) their placentas from non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (n = 7 litters per group).\
Statistical analysis was performed using the Mantel-Cox test for survival curves, and Kruskal-Wallis or ANOVA tests with correction for multiple comparisons. See also [Figures S1](#SD1){ref-type="supplementary-material"}--[S4](#SD1){ref-type="supplementary-material"}.](nihms-1610265-f0004){#F3}

![The Adoptive Transfer of Tregs Prevents Preterm Birth and Adverse Neonatal Outcomes\
(A) *Foxp3*^*DTR*^ dams underwent partial Treg depletion. On 14.5 and 16.5 dpc, *Foxp3*^*DTR*^ dams received an adoptive transfer of Tregs from wild-type mice.\
(B) Preterm birth rates of partially Treg-depleted *Foxp3*^*DTR*^ dams without or with the adoptive transfer of Tregs (n = 6--20 per group). Data are represented as means of percentages.\
(C) Percentage of survival from birth until 3 weeks postpartum for neonates born to partially Treg-depleted *Foxp3*^*DTR*^ dams without or with the adoptive transfer of Tregs (n = 6--20 per group).\
(D) *Foxp3*^*DTR*^ dams underwent partial Treg depletion. On 14.5 and 16.5 dpc, *Foxp3*^*DTR*^ dams received an adoptive transfer of Tregs from *EGFP* mice.\
(E) Representative gating and histograms showing adoptively transferred GFP+ Tregs in the decidua, myometrium, placenta, and peripheral tissues (peripheral blood mononuclear cells \[PBMCs\], uterine-draining lymph nodes \[ULNs\], and spleen) of recipient Treg-depleted dams. Statistical analysis was performed using the Mantel-Cox test for survival curves.](nihms-1610265-f0005){#F4}

![Maternal-Fetal Obstetrical Parameters upon Partial or Total Treg Depletion\
(A) *Foxp3*^*DTR*^ dams underwent partial or total Treg depletion until 17.5 dpc on which body temperature, blood pressure, and Doppler determinations were performed (n = 8--9 per group).\
(B and C) Body temperature (B) and mean blood pressure (C) of non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (n = 8--9 per group).\
(D--F) Representative Doppler image of the uterine artery (D), which was used to determine (E) maternal heart rate, and (F) uterine artery pulsatility index of non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (n = 8--9 per group).\
(G--I) Representative Doppler image of the umbilical artery (G), which was used to determine (H) fetal heart rate, and (I) umbilical artery pulsatility index in fetuses of non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (n = 24--27 per group).\
(J) Representative images of the spleens and ULNs from non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams (n = 3 per group).\
(K) Representative images of neonates born to non-Treg-depleted-, partially Treg-depleted-, and totally Treg-depleted-*Foxp3*^*DTR*^ dams on the day of birth (n = 3 per group). Red dotted squares indicate the presence of the milk band. Statistical analysis was performed using the Kruskal-Wallis or ANOVA tests with correction for multiple comparisons.](nihms-1610265-f0006){#F5}

![Depletion of Tregs Induces a Mild Systemic Inflammatory Response in the Absence of Intra-Amniotic Inflammation\
(A--H) *Foxp3*^*DTR*^ dams underwent partial or total Treg depletion. Controls were injected with sterile 13 PBS. Mice were euthanized approximately 4 h after the second DT or PBS injection, and maternal plasma samples and amniotic fluid were collected. Concentrations of (A) IL-6, (B) CCL2, (C) IL-1β, (D) TNF-α, (E) IFNγ, (F) CCL7, (G) IL-22, and (H) IL-10 in the maternal plasma (n = 7 per group). Data are shown as medians with interquartile ranges and minimum/maximum ranges. C57BL/6 dams were intravenously injected with recombinant mouse IFNγ (1.4 pg/100 μL), CCL7 (218 pg/100 μL), IL-22 (48 pg/100 μL), or a combination of all three. Controls were injected with 100 μL of sterile 13 PBS alone.\
(I) Gestational length of cytokine-injected dams. Data are shown as means with standard deviations (n = 3--6 per group).\
(J) Rate of early-term or full-term delivery of cytokine-injected dams (n = 3--6 per group).\
(K) Percentage of survival from birth until 3 weeks postpartum for neonates born to cytokine-injected dams (n = 3--6 litters per group).\
(L--S) Concentrations of (L) IL-6, (M) CXCL10, (N) CCL2, (O) IL-1β, (P) TNF-α, (Q) IFNγ, (R) IL-10, and (S) IL-4 in the amniotic fluid (n = 5--7 per group). Data are shown as medians with interquartile ranges and minimum/maximum ranges.\
Statistical analysis was performed using the Mantel-Cox test for survival curves, and Kruskal-Wallis or ANOVA tests with correction for multiple comparisons. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1610265-f0007){#F6}

![Depletion of Tregs Is Associated with Altered Systemic and Local Cellular Immune Responses and Dysregulation of Developmental and Cellular Processes in the Placenta\
*Foxp3*^*DTR*^ dams underwent partial or total Treg depletion. Controls were injected with sterile 13 PBS. Mice were euthanized approximately 4 h after the second injection and the decidua, myometrium, placenta, and peripheral blood were collected for flow cytometry (all tissues, n = 5--7 per group) or for RNA-seq analysis (placenta only, n = 5 per group).\
(A) Heatmap visualization of changes in the log2-transformed frequencies of immune cell subsets in the decidua, myometrium, placenta, and peripheral blood of partially and totally Treg-depleted *Foxp3*^*DTR*^ dams relative to controls. Red and green indicate increased and reduced abundance, respectively, relative to PBS controls.\
(B) Heatmap visualization of changes in gene expression in the placentas of partially and totally Treg-depleted *Foxp3*^*DTR*^ dams and controls. Red indicates gene upregulation and green indicates gene downregulation relative to the average value in the PBS group.\
(C) Volcano plot showing genes differentially expressed between placentas from partially Treg-depleted *Foxp3*^*DTR*^ dams and those from control dams.\
(D) Volcano plot showing genes differentially expressed between placental tissues from totally Treg-depleted *Foxp3*^*DTR*^ dams and those from control dams.\
(E) Network of biological processes dysregulated in the placentas of totally Treg-depleted *Foxp3*^*DTR*^ dams.\
Statistical analysis was performed using t-tests with false discovery rate adjustment. Asterisks indicate significant differences compared to controls after adjustment. See also [Figure S6](#SD1){ref-type="supplementary-material"} and [Tables S3](#SD2){ref-type="supplementary-material"}, [S4](#SD3){ref-type="supplementary-material"}, [S5](#SD4){ref-type="supplementary-material"}, [S6](#SD5){ref-type="supplementary-material"}, [S7](#SD6){ref-type="supplementary-material"}, and [S8](#SD7){ref-type="supplementary-material"}.](nihms-1610265-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                      SOURCE                                                                                                                                                                                               IDENTIFIER
  -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  Antibodies                                                                                                                                                                                                                                                                                                    
  CD45-AlexaFluor700; Clone HI30                                                                           BD Biosciences                                                                                                                                                                                       Cat\# 560566; RRID:AB_1645452
  CD3-APC-Cy7; Clone SK7                                                                                   BD Biosciences                                                                                                                                                                                       Cat\# 557832; RRID:AB_396890
  CD4-PE-CF594; Clone RPA-T4                                                                               BD Biosciences                                                                                                                                                                                       Cat\# 562316; RRID:AB_11154394
  CD8-PE; Clone RPA-T8                                                                                     BD Biosciences                                                                                                                                                                                       Cat\# 561949; RRID:AB_10897146
  CD25-PE-Cy7; Clone M-A251                                                                                BD Biosciences                                                                                                                                                                                       Cat\# 557741; RRID:AB_396847
  FoxP3-V450; Clone 259D/C7                                                                                BD Biosciences                                                                                                                                                                                       Cat\# 560459; RRID:AB_1645591
  L-17A-AlexaFluor488; Clone N49--653                                                                      BD Biosciences                                                                                                                                                                                       Cat\# 560489; RRID:AB_1645355
  gG1, κ Isotype Control-V450; Clone MOPC-21                                                               BD Biosciences                                                                                                                                                                                       Cat\# 560373; RRID:AB_1645606
  gG2b, κ Isotype Control-AlexaFluor 488; Clone 27--35                                                     BD Biosciences                                                                                                                                                                                       Cat\# 558716; RRID:AB_1645613
  CD3-APC-Cy7; Clone 145--2C11                                                                             BD Biosciences                                                                                                                                                                                       Cat\# 557596; RRID:AB_396759
  CD4-APC; Clone RM4--5                                                                                    BD Biosciences                                                                                                                                                                                       Cat\# 553051; RRID:AB_398528
  CD8-PE-CF594; Clone 53--6.7                                                                              BD Biosciences                                                                                                                                                                                       Cat\# 562283; RRID:AB_11152075
  CD25-PE; Clone 7D4                                                                                       Miltenyi Biotec                                                                                                                                                                                      Cat\# 130-118-550; RRID:AB_2784088
  Foxp3-V450; Clone MF23                                                                                   BD Biosciences                                                                                                                                                                                       Cat\# 561293; RRID:AB_10611728
  CD45-AF700; Clone 30-F11                                                                                 BD Biosciences                                                                                                                                                                                       Cat\# 560510; RRID:AB_1645208
  CD11b-BV737; Clone M1/70                                                                                 BD Biosciences                                                                                                                                                                                       Cat\# 564443; RRID:AB_2738811
  F4/80-APC-eFluor780; Clone BM8                                                                           eBioscience                                                                                                                                                                                          Cat\# 12-4801-82; RRID:AB_465923
  Ly6G-BV395; Clone 1A8                                                                                    BD Biosciences                                                                                                                                                                                       Cat\# 563978; RRID:AB_2716852
  CD11c-BV711; Clone HL3                                                                                   BD Biosciences                                                                                                                                                                                       Cat\# 563048; RRID:AB_2734778
  CD49b-PE-CF594; Clone DX5                                                                                BD Biosciences                                                                                                                                                                                       Cat\# 562453; RRID:AB_11153857
  CD19-BV421; Clone 1D3                                                                                    BD Biosciences                                                                                                                                                                                       Cat\# 562701; RRID:AB_2737731
  CD205-PerCP eFluor710; Clone 205yekta                                                                    eBioscience                                                                                                                                                                                          Cat\# 46-2051-82; RRID:AB_1834423
  NOS-PE; Clone CXNFT                                                                                      eBioscience                                                                                                                                                                                          Cat \# 12-5920-82; RRID:AB_2572642
  Arg1-FITC; Polyclonal                                                                                    R&D Systems                                                                                                                                                                                          Cat \# IC5868F; RRID:AB_10718118
  IFNγ-BV786; Clone XMG1.2                                                                                 BD Biosciences                                                                                                                                                                                       Cat\# 563773; RRID:AB_2738419
  IL10-BV605; Clone JES5--16E3                                                                             BD Biosciences                                                                                                                                                                                       Cat\# 564082; RRID:AB_2738582
  TNFα-PECy7; Clone MP6-XT22                                                                               BD Biosciences                                                                                                                                                                                       Cat\# 557644; RRID:AB_396761
  IL6-APC; Clone MP5--20F3                                                                                 BD Biosciences                                                                                                                                                                                       Cat\# 561367; RRID:AB_10679354
  CD3-BV650; Clone 145--2C11                                                                               BD Biosciences                                                                                                                                                                                       Cat\# 564378; RRID:AB_2738779
  CD4-PECy5; Clone RM4--5                                                                                  BD Biosciences                                                                                                                                                                                       Cat\# 553050; RRID:AB_394586
  CD8-APC-Cy7; Clone 53--6.7                                                                               BD Biosciences                                                                                                                                                                                       Cat\# 557654; RRID:AB_396769
  CD25-BV711; Clone PC61                                                                                   BD Biosciences                                                                                                                                                                                       Cat\# 740714; RRID:AB_2740396
  IL2-AF700; Clone JES6--5H4                                                                               BD Biosciences                                                                                                                                                                                       Cat\# 561287; RRID:AB_10679118
  IL4-BV421; Clone 11B11                                                                                   BD Biosciences                                                                                                                                                                                       Cat\# 562915; RRID:AB_2737889
  Foxp3-AF488; Clone MF23                                                                                  BD Biosciences                                                                                                                                                                                       Cat\# 560403; RRID:AB_1645192
  IL17A-BV786; Clone TC11--18H10                                                                           BD Biosciences                                                                                                                                                                                       Cat\# 564171; RRID:AB_2738642
  IgG2a, κ Isotype Control-PE; Clone eBR2a                                                                 eBioscience                                                                                                                                                                                          Cat\# 12-4321-80; RRID:AB_1834380
  IgG Control-FITC; Polyclonal                                                                             R&D Systems                                                                                                                                                                                          Cat\# IC016F; RRID:AB_1267476
  IgG1, κ Isotype Control-BV786; Clone R3--34                                                              BD Biosciences                                                                                                                                                                                       Cat\# 563847; RRID:N/A
  IgG2b, κ Isotype Control-BV605; Clone R35--38                                                            BD Biosciences                                                                                                                                                                                       Cat\# 563145; RRID:N/A
  IgG1, κ Isotype Control-PE-Cy7; Clone R3--34                                                             BD Biosciences                                                                                                                                                                                       Cat\# 557645; RRID:AB_396762
  IgG1, κ Isotype Control-APC; Clone R3--34                                                                BD Biosciences                                                                                                                                                                                       Cat\# 554686; RRID:AB_39857
  IgG1, κ Isotype Control-BV421; Clone R3--34                                                              BD Biosciences                                                                                                                                                                                       Cat\# 562868; RRID:AB_2734711
  IgG2b, κ Isotype Control AF488; Clone A95--1                                                             BD Biosciences                                                                                                                                                                                       Cat\# 557726; RRID:AB_396834
  CD45-APC-Cy7; Clone 2D1                                                                                  BD Biosciences                                                                                                                                                                                       Cat\# 557833, RRID: AB_396891
  CD3-PerCP-Cy5.5; Clone SK7                                                                               BD Biosciences                                                                                                                                                                                       Cat\# 340949, RRID: AB_400190
  CD4-BUV737; Clone SK3                                                                                    BD Biosciences                                                                                                                                                                                       Cat\# 564305, RRID: AB_2713927
  CD8-BUV395; Clone RPA-T8                                                                                 BD Biosciences                                                                                                                                                                                       Cat\# 563795, RRID: AB_2722501
  CD25-PE-Cy7; Clone M-A251                                                                                BD Biosciences                                                                                                                                                                                       Cat\# 557741, RRID: AB_396847
  IL-17A-BV650; Clone N49--653                                                                             BD Biosciences                                                                                                                                                                                       Cat\# 563746, RRID: AB_2738402
  IgG1, κ Isotype Control-BV650; Clone X40                                                                 BD Biosciences                                                                                                                                                                                       Cat\# 563231, RRID: N/A
  FoxP3-Alexa Fluor 647; Clone 295DD/C7                                                                    BD Biosciences                                                                                                                                                                                       Cat\# 560045, RRID: AB_1645411
  IgG1, κ Isotype Control-Alexa Fluor 647; Clone MOPC-21                                                   BD Biosciences                                                                                                                                                                                       Cat\# 557714, RRID: AB_396823
  FoxP3-Alexa Fluor 488; Clone 295DD/C7                                                                    BD Biosciences                                                                                                                                                                                       Cat\# 560047, RRID: AB_1645349
  IgG1, κ Isotype Control-Alexa Fluor 488; Clone MOPC-21                                                   BD Biosciences                                                                                                                                                                                       Cat\# 557702, RRID: AB_396811
  Biological Samples                                                                                                                                                                                                                                                                                            
  Human placental basal plate (decidua basalis) and chorioamniotic membrane (decidua parietalis) samples   Perinatology Research Branch, an intramural program of the *Eunice Kennedy Shriver* NICHD, NIH, DHHS, Wayne State University (Detroit, MI, USA), and the Detroit Medical Center (Detroit, MI, USA)   N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                                                                                                                                 
  Diphtheria toxin (*Corynebacterium diptheriae*)                                                          Sigma-Aldrich                                                                                                                                                                                        Cat\# D0564
  Diphtheria toxin (*Corynebacterium diptheriae*)                                                          Calbiochem, EMD Millipore Corp                                                                                                                                                                       Cat\# 322326-1MG
  Diphtheria toxin (*Corynebacterium diptheriae*)                                                          Enzo Life Sciences                                                                                                                                                                                   Cat\# BML-G135
  Lipopolysaccharides from *Escherichia coli* O55:B5                                                       Sigma-Aldrich                                                                                                                                                                                        Cat\# L6259-1MG
  BD Horizon Fixable Viability Stain 510                                                                   BD Biosciences                                                                                                                                                                                       Cat\# 564406
  BD Horizon Fixable Viability Stain 575V                                                                  BD Biosciences                                                                                                                                                                                       Cat\# 565694
  LIVE/DEAD Fixable Green Dead Cell Stain Kit                                                              Invitrogen, Thermo Fisher Scientific                                                                                                                                                                 Cat\# L23101
  CellTrace Violet Cell Proliferation Kit                                                                  Molecular Probes, Thermo Fisher Scientific                                                                                                                                                           Cat\# C34557
  IL2 Recombinant Human Protein                                                                            GIBCO, Thermo Fisher Scientific                                                                                                                                                                      Cat\# PHC0026
  2-Mercaptoethanol                                                                                        GIBCO, Thermo Fisher Scientific                                                                                                                                                                      Cat\# 21985-023
  Mouse IL-2                                                                                               Miltenyi Biotec                                                                                                                                                                                      Cat\# 130-094-054
  Animal Free Recombinant Mouse IFNγ                                                                       PeproTech                                                                                                                                                                                            Cat\# AF-315-05
  Recombinant Mouse CCL7                                                                                   R&D Systems                                                                                                                                                                                          Cat\# 456-MC-010/CF
  Recombinant Mouse IL-22                                                                                  Biolegend                                                                                                                                                                                            Cat\# 576202
  Deposited Data                                                                                                                                                                                                                                                                                                
  RNA-Seq data of murine placental tissues                                                                 This manuscript                                                                                                                                                                                      GEO: GSE145357
  Experimental Models: Organisms/Strains                                                                                                                                                                                                                                                                        
  B6.129(Cg)-*Foxp3*^*tm3(DTR/GFP)Ayr*^ (*Foxp3*^*DTR*^)                                                   The Jackson Laboratory                                                                                                                                                                               Stock\# 016958
  C57BL/6-Tg (CAG-EGFP)131Osb/LeySopJ *(EGFP)*                                                             The Jackson Laboratory                                                                                                                                                                               Stock\# 006567
  C57BL/6                                                                                                  The Jackson Laboratory                                                                                                                                                                               Stock\# 000664
  BALB/cBy                                                                                                 The Jackson Laboratory                                                                                                                                                                               Stock\# 001026
  Other                                                                                                                                                                                                                                                                                                         
  Stain buffer                                                                                             BD Biosciences                                                                                                                                                                                       Cat\# 554656
  Foxp3/Transcription Factor Fixation/Permeabilization solution                                            eBioscience                                                                                                                                                                                          Cat\# 00-5523-00
  CD4+ CD25+ Regulatory T Cell Isolation Kit, mouse                                                        Miltenyi Biotec                                                                                                                                                                                      Cat\# 130-091-041
  Treg Expansion Kit, mouse (CD3/CD28 MACSiBead particles)                                                 Miltenyi Biotec                                                                                                                                                                                      Cat\# 130-095-925
  Dynabeads Human T-Activator CD3/CD28 for T Cell Expansion and Activation                                 GIBCO, Thermo Fisher Scientific                                                                                                                                                                      Cat\# 11161D
  ProcartaPlex Mouse Cytokine & Chemokine Panel 1A 36-plex                                                 ThermoFisher                                                                                                                                                                                         Cat\# EPX360-26092-901

###### Highlights

-   Tregs are reduced at the maternal-fetal interface in idiopathic preterm labor/birth

-   The loss of Tregs induces a fraction of preterm births

-   The loss of Tregs induces adverse fetal and neonatal outcomes

-   Tregs modulate systemic and local immune responses in the third period of pregnancy
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